To appraise the clinical and cost effectiveness of tofacitinib within its marketing authorisation for treating active psoriatic arthritis in adults whose disease has not responded adequately to previous disease-modifying anti-rheumatic drug (DMARD) therapy, or for whom DMARDs are not tolerated or contraindicated.
Status Proposed
Process STA
ID number 1220

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
19 September 2017 - 17 October 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance